Dr Luca Gianni speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the updated results from the NeoTRIPaPDL1 trial, which examined the addition of atezolizumab with neoadjuvant chemotherapy in the treatment of triple-negative breast cancer.
He describes the main aim of the study and reports that the pathologic complete response rate was similar irrespective of the addition of atezolizumab.
Dr Gianni also discusses the adverse events associated with this regimen and the differences between the use of pembrolizumab and atezolizumab in this disease setting.
He anticipates that data on event-free survival will be available in the next few years and the incorporation of molecular testing in future studies.
Watch the press conference here.
Read more about the study here.